Bringing the Patent Abuse Playbook to a New Category of Blockbuster Products A February 2024 analysis published in JAMA Network found brand name drug makers marketing a new category of weight loss drugs, glucagon-like peptide 1 (GLP-1) receptor agonists, are increasingly utilizing device patents to build patent thickets around these products to create and elongate periods of monopoly pricing power despite the drugs effectively being older diabetes medications repackaged for a different indication
Specifically, in the extracellular half of GLP-2R, TM1 forms at least one additional helical turn, thereby moving toward TM2 (5 , measured by C of the residue at 1.33b) and bending down toward GLP-2
Out of the thousands of beauty products on Sephora.com, a very small group has hit or exceeded the 1 million likes mark
For instance, in January 2025, the FDA approved semaglutide (Ozempic) as a medication to reduce the risk of kidney failure, kidney disease progression, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease (CKD)